Business Description
Tango Therapeutics is a Boston-based drug discovery company focused on developing targeted cancer treatments for patients with limited options. Its lead programs include two PRMT5 inhibitors currently in clinical trials for pancreatic, lung, and brain cancers, as well as a separate therapy designed to help the immune system recognize and attack lung tumors driven by a specific genetic mutation. Founded in 2017, the company builds its pipeline around matching treatments to the precise genetic profiles of cancer patients.
